uniQure N.V. (QURE) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
UroGen Pharma (URGN) has outperformed uniQure N.V. (QURE) over the past year, gaining 6.9% versus a loss of 30.4%. Over five years, URGN leads with a +127.8% price change compared with -32.9% for QURE. uniQure N.V. is the larger company by market cap ($1.36 billion vs $1.36 billion), about 1.0 times the size, while UroGen Pharma is growing revenue faster (+21.4% vs -40.6%).
UroGen Pharma converts more of its revenue into profit, with a net margin of -139.8% versus -1236.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QURE | URGN |
|---|---|---|
| Share price | $19.35 | $27.65 |
| Market cap | $1.36B | $1.36B |
| 1-day change | -4.35% | -12.86% |
| YTD return | -19.14% | +18.06% |
| 1-year return | -30.42% | +6.88% |
| 5-year return | -32.86% | +127.76% |
| Forward P/E | — | 11.08 |
| EPS (TTM) | $-3.51 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $16.10M | $109.79M |
| Revenue growth (YoY) | -40.64% | +21.45% |
| Net income (latest FY) | $-198.97M | $-153.49M |
| Gross margin | 89.53% | 88.66% |
| Operating margin | -1151.38% | -113.73% |
| Net margin | -1236.00% | -139.81% |
| 52-week high | $51.72 | $50.81 |
| 52-week low | $8.73 | $16.50 |
| Distance from 52-week high | -62.59% | -45.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +207.03% | +119.57% |
| Average volume | 2.26M | 1.11M |
| Shares outstanding | 70.14M | 49.05M |
| Employees | 221 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed QURE by 37.3 percentage points over the past year.
- UroGen Pharma is more profitable, keeping -139.8 cents of every revenue dollar as net income versus -1236.0 cents for uniQure N.V..
- UroGen Pharma grew revenue faster in its latest fiscal year (+21.45% vs -40.64%).
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
QURE vs URGN FAQ
Which is bigger, uniQure N.V. or UroGen Pharma?
uniQure N.V. (QURE) is larger, with a market capitalization of $1.36B compared with $1.36B for UroGen Pharma (URGN).
Which stock has performed better over the past year, QURE or URGN?
URGN returned +6.88% over the past 12 months, compared with -30.42% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are uniQure N.V. and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.